{"protocolSection": {"identificationModule": {"nctId": "NCT03899155", "orgStudyIdInfo": {"id": "CA209-8TT"}, "secondaryIdInfos": [{"id": "2018-004362-34", "type": "EUDRACT_NUMBER"}], "organization": {"fullName": "Bristol-Myers Squibb", "class": "INDUSTRY"}, "briefTitle": "Pan Tumor Rollover Study", "officialTitle": "Pan-Tumor Study for Long-term Treatment of Cancer Patients Who Have Participated in BMS Sponsored Trials Investigating Nivolumab and Other Cancer Therapies"}, "sponsorCollaboratorsModule": {"responsibleParty": {"type": "SPONSOR"}, "leadSponsor": {"name": "Bristol-Myers Squibb", "class": "INDUSTRY"}, "collaborators": [{"name": "Exelixis", "class": "INDUSTRY"}, {"name": "Novartis", "class": "INDUSTRY"}, {"name": "Clovis Oncology, Inc.", "class": "INDUSTRY"}, {"name": "Janssen Pharmaceuticals", "class": "INDUSTRY"}]}, "descriptionModule": {"briefSummary": "Main Objective of this study is to examine long-term safety of nivolumab monotherapy including combinations and other cancer therapies in various tumor types."}, "conditionsModule": {"conditions": ["Cancer"], "keywords": ["Rollover", "pan-tumor"]}, "designModule": {"studyType": "INTERVENTIONAL", "phases": ["PHASE2"], "designInfo": {"allocation": "NON_RANDOMIZED", "interventionModel": "PARALLEL", "primaryPurpose": "TREATMENT", "maskingInfo": {"masking": "NONE"}}, "enrollmentInfo": {"count": 1500, "type": "ESTIMATED"}}, "armsInterventionsModule": {"armGroups": [{"label": "A1: Nivolumab Monotherapy Dose 1", "type": "EXPERIMENTAL", "interventionNames": ["Drug: Nivolumab"]}, {"label": "A2: Nivolumab Monotherapy Dose 2", "type": "EXPERIMENTAL", "interventionNames": ["Drug: Nivolumab"]}, {"label": "B1: Nivolumab + Ipilimumab", "type": "EXPERIMENTAL", "interventionNames": ["Drug: Nivolumab", "Drug: Ipilimumab"]}, {"label": "B2: Nivolumab + Ipilimumab + Cabozantinib", "type": "EXPERIMENTAL", "interventionNames": ["Drug: Nivolumab", "Drug: Ipilimumab", "Drug: Cabozantinib"]}, {"label": "B3: Nivolumab + Ipilimumab + Trametinib", "type": "EXPERIMENTAL", "interventionNames": ["Drug: Nivolumab", "Drug: Ipilimumab", "Drug: Trametinib"]}, {"label": "C1: Relatlimab + Nivolumab Fixed Dose Combination Dose 1", "type": "EXPERIMENTAL", "interventionNames": ["Drug: Nivolumab + Relatlimab"]}, {"label": "C3: Relatlimab + Nivolumab Fixed Dose Combination Dose 2", "type": "EXPERIMENTAL", "interventionNames": ["Drug: Nivolumab + Relatlimab"]}, {"label": "C2: Relatlimab + Nivolumab Single Agent Vial (SAV) Dose 1", "type": "EXPERIMENTAL", "interventionNames": ["Drug: Nivolumab", "Drug: Relatlimab"]}, {"label": "C4: Relatlimab + Nivolumab SAV Dose 2", "type": "EXPERIMENTAL", "interventionNames": ["Drug: Nivolumab", "Drug: Relatlimab"]}, {"label": "C5: Relatlimab + Nivolumab + Ipilimumab", "type": "EXPERIMENTAL", "interventionNames": ["Drug: Nivolumab", "Drug: Ipilimumab"]}, {"label": "C6: Relatlimab + Nivolumab + Capecitabine", "type": "EXPERIMENTAL", "interventionNames": ["Drug: Nivolumab + Relatlimab", "Drug: Capecitabine"]}, {"label": "C7: Relatlimab + Nivolumab SAV Dose 3", "type": "EXPERIMENTAL", "interventionNames": ["Drug: Nivolumab", "Drug: Relatlimab"]}, {"label": "C10: Relatlimab + Nivolumab SAV Dose 4", "type": "EXPERIMENTAL", "interventionNames": ["Drug: Nivolumab", "Drug: Relatlimab"]}, {"label": "C12: Relatlimab + Nivolumab SAV Dose 5", "type": "EXPERIMENTAL", "interventionNames": ["Drug: Nivolumab", "Drug: Relatlimab"]}, {"label": "C8: Relatlimab + Nivolumab SAV + PDCT Dose 1", "type": "EXPERIMENTAL", "interventionNames": ["Drug: Nivolumab", "Drug: Relatlimab"]}, {"label": "C9: Relatlimab + Nivolumab SAV + Bevacizumab", "type": "EXPERIMENTAL", "interventionNames": ["Drug: Nivolumab", "Drug: Relatlimab", "Drug: Bevacizumab"]}, {"label": "C11: Relatlimab + Nivolumab SAV + PDCT Dose 2", "type": "EXPERIMENTAL", "interventionNames": ["Drug: Nivolumab", "Drug: Relatlimab"]}, {"label": "D1: Nivolumab + Temozolomide", "type": "EXPERIMENTAL", "interventionNames": ["Drug: Nivolumab", "Drug: Temozolomide"]}, {"label": "D2: Nivolumab + Rucaparib", "type": "EXPERIMENTAL", "interventionNames": ["Drug: Nivolumab", "Drug: Rucaparib"]}, {"label": "D3: Nivolumab + Daratumumab", "type": "EXPERIMENTAL", "interventionNames": ["Drug: Nivolumab", "Drug: Daratumumab"]}, {"label": "D4: Nivolumab + Bevacizumab", "type": "EXPERIMENTAL", "interventionNames": ["Drug: Nivolumab"]}, {"label": "E1: Bevacizumab Monotherapy", "type": "EXPERIMENTAL", "interventionNames": ["Drug: Bevacizumab"]}, {"label": "E2: Regorafinib Monotherapy", "type": "EXPERIMENTAL", "interventionNames": ["Drug: Regorafinib"]}, {"label": "E4: Leucovorin + Oxaliplatin + Fluorouracil", "type": "EXPERIMENTAL", "interventionNames": ["Drug: Leucovorin", "Drug: Fluorouracil", "Drug: Oxaliplatin"]}, {"label": "E5: Enzalutamide Monotherapy", "type": "EXPERIMENTAL", "interventionNames": ["Drug: Enzalutamide"]}, {"label": "E6: Sunitinib Monotherapy", "type": "EXPERIMENTAL", "interventionNames": ["Drug: Sunitinib"]}, {"label": "E7: Rucaparib Monotherapy", "type": "EXPERIMENTAL", "interventionNames": ["Drug: Rucaparib"]}, {"label": "E8: Capecitabine Monotherapy", "type": "EXPERIMENTAL", "interventionNames": ["Drug: Capecitabine"]}, {"label": "E9: Cabozantinib Monotherapy", "type": "EXPERIMENTAL", "interventionNames": ["Drug: Cabozantinib"]}, {"label": "E10: Pemetrexed Monotherapy", "type": "EXPERIMENTAL", "interventionNames": ["Drug: Pemetrexed"]}, {"label": "E11: Pembrolizumab Monotherapy", "type": "EXPERIMENTAL", "interventionNames": ["Drug: Pembrolizumab"]}, {"label": "E3: Leucovorin + Fluorouracil", "type": "EXPERIMENTAL", "interventionNames": ["Drug: Leucovorin"]}], "interventions": [{"type": "DRUG", "name": "Nivolumab", "description": "Specified dose on specified days", "armGroupLabels": ["A1: Nivolumab Monotherapy Dose 1", "A2: Nivolumab Monotherapy Dose 2", "B1: Nivolumab + Ipilimumab", "B2: Nivolumab + Ipilimumab + Cabozantinib", "B3: Nivolumab + Ipilimumab + Trametinib", "C10: Relatlimab + Nivolumab SAV Dose 4", "C11: Relatlimab + Nivolumab SAV + PDCT Dose 2", "C12: Relatlimab + Nivolumab SAV Dose 5", "C2: Relatlimab + Nivolumab Single Agent Vial (SAV) Dose 1", "C4: Relatlimab + Nivolumab SAV Dose 2", "C5: Relatlimab + Nivolumab + Ipilimumab", "C7: Relatlimab + Nivolumab SAV Dose 3", "C8: Relatlimab + Nivolumab SAV + PDCT Dose 1", "C9: Relatlimab + Nivolumab SAV + Bevacizumab", "D1: Nivolumab + Temozolomide", "D2: Nivolumab + Rucaparib", "D3: Nivolumab + Daratumumab", "D4: Nivolumab + Bevacizumab"], "otherNames": ["BMS-936558-01"]}, {"type": "DRUG", "name": "Ipilimumab", "description": "Specified dose on specified days", "armGroupLabels": ["B1: Nivolumab + Ipilimumab", "B2: Nivolumab + Ipilimumab + Cabozantinib", "B3: Nivolumab + Ipilimumab + Trametinib", "C5: Relatlimab + Nivolumab + Ipilimumab"]}, {"type": "DRUG", "name": "Cabozantinib", "description": "Specified dose on specified days", "armGroupLabels": ["B2: Nivolumab + Ipilimumab + Cabozantinib", "E9: Cabozantinib Monotherapy"]}, {"type": "DRUG", "name": "Trametinib", "description": "Specified dose on specified days", "armGroupLabels": ["B3: Nivolumab + Ipilimumab + Trametinib"]}, {"type": "DRUG", "name": "Relatlimab", "description": "Specified dose on specified days", "armGroupLabels": ["C10: Relatlimab + Nivolumab SAV Dose 4", "C11: Relatlimab + Nivolumab SAV + PDCT Dose 2", "C12: Relatlimab + Nivolumab SAV Dose 5", "C2: Relatlimab + Nivolumab Single Agent Vial (SAV) Dose 1", "C4: Relatlimab + Nivolumab SAV Dose 2", "C7: Relatlimab + Nivolumab SAV Dose 3", "C8: Relatlimab + Nivolumab SAV + PDCT Dose 1", "C9: Relatlimab + Nivolumab SAV + Bevacizumab"], "otherNames": ["BMS-986016-01"]}, {"type": "DRUG", "name": "Nivolumab + Relatlimab", "description": "Specified dose on specified days", "armGroupLabels": ["C1: Relatlimab + Nivolumab Fixed Dose Combination Dose 1", "C3: Relatlimab + Nivolumab Fixed Dose Combination Dose 2", "C6: Relatlimab + Nivolumab + Capecitabine"], "otherNames": ["BMS-986213"]}, {"type": "DRUG", "name": "Capecitabine", "description": "Specified dose on specified days", "armGroupLabels": ["C6: Relatlimab + Nivolumab + Capecitabine", "E8: Capecitabine Monotherapy"]}, {"type": "DRUG", "name": "Bevacizumab", "description": "Specified dose on specified days", "armGroupLabels": ["C9: Relatlimab + Nivolumab SAV + Bevacizumab", "E1: Bevacizumab Monotherapy"]}, {"type": "DRUG", "name": "Temozolomide", "description": "Specified dose on specified days", "armGroupLabels": ["D1: Nivolumab + Temozolomide"]}, {"type": "DRUG", "name": "Rucaparib", "description": "Specified dose on specified days", "armGroupLabels": ["D2: Nivolumab + Rucaparib", "E7: Rucaparib Monotherapy"]}, {"type": "DRUG", "name": "Daratumumab", "description": "Specified dose on specified days", "armGroupLabels": ["D3: Nivolumab + Daratumumab"]}, {"type": "DRUG", "name": "Regorafinib", "description": "Specified dose on specified days", "armGroupLabels": ["E2: Regorafinib Monotherapy"]}, {"type": "DRUG", "name": "Leucovorin", "description": "Specified dose on specified days", "armGroupLabels": ["E3: Leucovorin + Fluorouracil", "E4: Leucovorin + Oxaliplatin + Fluorouracil"]}, {"type": "DRUG", "name": "Fluorouracil", "description": "Specified dose on specified days", "armGroupLabels": ["E4: Leucovorin + Oxaliplatin + Fluorouracil"]}, {"type": "DRUG", "name": "Oxaliplatin", "description": "Specified dose on specified days", "armGroupLabels": ["E4: Leucovorin + Oxaliplatin + Fluorouracil"]}, {"type": "DRUG", "name": "Enzalutamide", "description": "Specified dose on specified days", "armGroupLabels": ["E5: Enzalutamide Monotherapy"]}, {"type": "DRUG", "name": "Sunitinib", "description": "Specified dose on specified days", "armGroupLabels": ["E6: Sunitinib Monotherapy"]}, {"type": "DRUG", "name": "Pemetrexed", "description": "Specified dose on specified days", "armGroupLabels": ["E10: Pemetrexed Monotherapy"]}, {"type": "DRUG", "name": "Pembrolizumab", "description": "Specified dose on specified days", "armGroupLabels": ["E11: Pembrolizumab Monotherapy"]}]}, "eligibilityModule": {"eligibilityCriteria": "Inclusion Criteria:\n\n* Signed Written Informed Consent.\n* Eligible to receive continued study treatment per the Parent Study, including treatment beyond progression per investigator assessment in the Parent Study.\n* On treatment hold in the Parent Study following long-lasting response or are eligible for treatment rechallenge as defined in the Parent Study.\n* WOCBP and male participants who are sexually active must agree to follow instructions for method(s) of contraception as described below and included in the ICF.\n\nExclusion Criteria:\n\n* Participant is not eligible for study treatment per the Parent Study eligibility criteria.\n* Participants not receiving clinical benefit as assessed by the Investigator.\n* Any clinical adverse event (AE), laboratory abnormality, or intercurrent illness which, in the opinion of the Investigator, indicates that participation in the study is not in the best interest of the participant.\n* Other protocol-defined Inclusion/Exclusion Criteria apply", "healthyVolunteers": false, "sex": "ALL", "minimumAge": "18 Years", "stdAges": ["ADULT", "OLDER_ADULT"]}, "contactsLocationsModule": {"centralContacts": [{"name": "BMS Study Connect Contact http://www.bmsstudyconnect.com/", "role": "CONTACT", "phone": "855-907-3286", "email": "Clinical.Trials@bms.com"}, {"name": "First line of the email MUST contain NCT# and Site#", "role": "CONTACT"}], "overallOfficials": [{"name": "Bristol-Myers Squibb", "affiliation": "Bristol-Myers Squibb", "role": "STUDY_DIRECTOR"}]}, "referencesModule": {"seeAlsoLinks": [{"label": "BMS Clinical Trial Information", "url": "https://www.bms.com/researchers-and-partners/clinical-trials-and-research.html"}, {"label": "BMS Clinical Trial Patient Recruiting", "url": "http://www.BMSClinicalTrials.com"}]}}, "hasResults": false}